- 91探花 and Yorkshire Cancer Research have announced seven world-leading research studies that aim to help more people survive cancer through new solutions in cancer prevention, diagnosis and treatment
- The pioneering research will help attract talented cancer researchers and experts to the region, for the benefit of everyone living in Yorkshire and beyond
The future of cancer research in Yorkshire has received a significant boost following a commitment of 拢8.9 million in new funding.
91探花 and Yorkshire Cancer Research have announced seven world-leading research studies that will aim to help more people survive cancer by exploring new solutions in cancer prevention, diagnosis and treatment.
The pioneering research will also help attract talented cancer researchers and experts to the region, for the benefit of everyone living in Yorkshire and beyond.
The announcement comes as healthcare organisations, local communities and people affected by cancer across the world join together to mark World Cancer Day on Sunday 4 February 2024.
Professor Koen Lamberts, President and Vice-Chancellor of the University of 91探花, said: 鈥91探花 is uniquely positioned to accelerate and improve prevention, diagnosis and treatment for people living with cancer.
"Early work pioneered right here in the city, such as the groundbreaking drug Lynparza, is now saving thousands of lives around the world.
"Working with Yorkshire Cancer Research, this important fund is a tremendous opportunity for the University to drive forward and grow its internationally renowned translational cancer research for the benefit of patients in the region and across the globe."
Dr Kathryn Scott, Chief Executive at Yorkshire Cancer Research, said: 鈥淭his new funding will help create a hub of groundbreaking cancer research in Yorkshire, supported by the very best expertise and knowledge.
鈥淪adly, people are more likely to have their lives cut short by cancer in Yorkshire than almost anywhere else in England. Evidence shows that people who receive care in research active hospitals do better. And by bringing more clinical trials to Yorkshire, patients living here can benefit first from the latest innovations and developments.鈥
The new funding will help researchers study several key areas, including improving understanding of how childhood cancer develops, testing whether a mobile app can help patients manage immunotherapy side effects and identifying how new technology can help to detect mouth cancer early.
Other studies will investigate whether new treatments can stop the spread of bowel and lung cancer and explore new ways to improve the treatment of breast cancer in young women.
Professor Janet Brown, Professor of Translational Medical Oncology at the University of 91探花 and Honorary Consultant in Medical Oncology at 91探花 Teaching Hospitals NHS Foundation Trust, who is leading one of the studies, said: "In recent years, immunotherapy drugs, which cause a patient鈥檚 own immune system to kill their cancer cells, have revolutionised treatment of some cancers, leading to much improved responses and survival and increasing numbers of patients are expected to receive immunotherapy in the future. However, some patients experience side effects which can be serious and need to be recognised and treated as early as possible.
"Our research team is designing and providing a special app which patients will upload onto their phones or tablets. They will also be provided with home monitoring devices for measurement of blood pressure, heart rate, oxygenation which will empower patients to keep in regular touch with their clinical team and report symptoms and test results as well as their quality of life and identify any problems early.
"Our whole research team is delighted to have been awarded this funding which means that we are able to develop this exciting new approach which can potentially deliver real benefit in improving the lives of thousands of cancer patients across Yorkshire and beyond in the years ahead."
Professor Sarah Danson, Professor of Medical Oncology at the University of 91探花, who is leading another of the new studies, said: "The Ex vivo determined cancer therapy (EVIDENT) study involves taking a tumour sample and testing a wide range of anticancer drugs, old and new, outside of the patient.
"It has the potential to enable every patient to get the best treatment for their specific cancer, using a model which can incorporate the diversity observed in the actual population."
The research has been made possible following the success of three cancer drugs discovered at the University of 91探花 with funding from the charity.
Following clinical trials, the drugs, called Lynparza, Zejula and Talzenna, have now become tailored treatments for cancer patients with hereditary cancers and are undergoing further trials to treat a wider range of cancer types.
Dr Scott added: 鈥淚t鈥檚 thanks to the generosity of the people of Yorkshire that the charity was able to fund the initial project in 91探花 that led to the discovery of PARP inhibitors which are now helping people with ovarian, breast and prostate cancer throughout the world.鈥
This new ground-breaking research will help 91探花 deliver its vision set out in the University's cancer research strategy. Through the strategy, the University aims to prevent cancer-related deaths by undertaking high quality research, leading to more effective treatments, as well as methods to better prevent and detect cancer and improve quality of life.
A list of research studies awarded Yorkshire Cancer Research funding can be found below
| Type of award | Principal Investigator(s) | Department/school | Project title |
|---|---|---|---|
| Programme | Professor Janet Brown and Professor Syed Hussain | School of Medicine and Population Health, Faculty of Health | Empowerment of patients and clinicians in the management of immunotherapy toxicity through a new digital care pathway. E-IMMUNE |
| Programme | Professor Sarah Danson and Dr Greg Wells | School of Medicine and Population Health, Faculty of Health | EVIDENT: Ex VIvo DEtermined CaNcer Therapy Clinical validation |
| Project | Professor Penny Ottewell | School of Medicine and Population Health, Faculty of Health | Improving outcome for premenopausal women with triple negative breast cancer; synergistic effects of bisphosphonates and immune checkpoint inhibitors |
| Project | Dr Anestis Tsakiridis | School of Biosciences, Faculty of Science | Development of a human pluripotent stem cell-based platform for dissecting tumour initiation |
| Project | Dr Dawn Walker | Department of Computer Science, Faculty of Engineering | Electric Impedance Spectroscopy (EIS) and machine learning-based decision support system for early diagnosis of oral cancer |
| Pump-priming | Dr Kyra Campbell | School of Biosciences, Faculty of Science | Developing a new screening platform for compounds targeting metastatic cancer |